This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Need Learning Now?

Join us for this free-to-attend webinar series June 8-10 featuring 8 live scientific demonstrations presented by leading scientists and researchers to help accelerate your next generation antibodies to commercial success.

You won't want to miss a moment of this webinar series focused on 3 primary themes:

Antibody Discovery, Selection and Screening - Monday, June 8
  • Synthetic DNA Technologies Enable Fast and Responsive SARS-CoV-2 Antibody Discovery and Optimization      
  • Drug-like Antibodies Directly from Selections: Specifica’s Generation 3 Antibody Platform     
  • Rapid Discovery of a Diverse Panel of Antibodies Against Membrane Targets using the Beacon® System
Learn more
Bispecific Antibodies - Tuesday, June 9
  • Monitoring of Glycosylation using Site Specific Approaches
  • A Bispecific SNIPER™ Demonstrates Preclinical Efficacy Through the Selective Elimination of Tumor Tregs
  • Critical Role of SARS-CoV-2 Spike Protein in Developing Drugs, Serological Tests and Vaccines for COVID-19

Learn more
Computational Approaches and Machine Learning in Antibody and Protein Engineering - Wednesday, June 10
  • Cellular Screening Platforms for Engineering T Cell Receptors and Chimeric Antigen Receptors
  • A Deep Learning Approach to Designing Libraries of Developable Antibodies for Discovery
Learn more

The Future of Antibody Engineering and Therapeutics - eBook Series

Introducing the first in our new Antibody Therapeutics eBook Series. Each edition we will be taking an in-depth look at one area of antibody engineering and therapeutics, and this time we are focusing on how the latest technologies and strategies are shaping the future of the industry.


  • Looking to 2030 Survey Report
  • The response of the antibody therapeutic industry to COVID-19
  • Emerging technologies in antibody engineering and therapeutics
  • Novel technologies and approaches for optimizing antibody discovery